菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Scientific Poster Download

modified on Oct. 17, 2023

Discovery of a Cynomolgus Monkey-Cross-Reactive Anti-Human CD3 mAb for T Cell Engagers
Qin Mei, George Wang, Jieying Liu, Yunying Chen, Jijie Gu, and Siwei Nie
Biologics Innovation and Discovery, WuXi Biologics

Anti-CD3 based T cell engager antibodies can redirect cytotoxic activity of T cells in a non-MHC restricted fashion to kill tumor cells effectively. Therefore, the discovery of an anti-CD3 antibody capable of activating T cells in the presence of tumor cells is highly desirable and in recent years, many anti-CD3 bispecific antibodies (bsAbs) entered clinical trials. Here, we showcase the discovery of an anti-CD3 monoclonal antibody (mAb) specific to a unique epitope on the epsilon chain of CD3 originating from the WuXi Biologics advanced hybridoma platform.

 

This scientific poster was originally presented during the 2023 Chinese Antibody Society Conference

Discuss This Poster

To discuss the data in this poster, please complete the form on the following page to connect with our experts.

Connect with our Experts